CorMedix Inc. · NASDAQ:CRMD

CorMedix — Investor Presentation (January 2019)

23 slides from CorMedix's investor presentation, January 2019

  1. Slide 1: Harnessing Taurolidine Technology

    Slide 1: Harnessing Taurolidine Technology

    HarnessingTaurolidine Technology Leading Development of Novel Anti-Infective Products in the Era of Increasing Bacterial Resistance January 2019 CORMEDIX 1

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    FORWARD-LOOKING STATEMENTS This presentation contains certain statements that constitute forward-looking statements within the meaning of the federal securities laws. Statements that are not historical facts, including statements about our beliefs and expectations, are forward-looking statements. Th

  3. Slide 3: Financial Summary

    Slide 3: Financial Summary

    FINANCIAL SUMMARY Founded January 2006 Exchange: Ticker NYSE American: CRMD Headquarters Berkeley Heights, NJ Employees (U.S.) 21 Common Stock O/S 105.3 Million Pref/CS Equivalents 18.3 Million Warrants Outstanding 16.6 Million $6.4 Million ($13.9 Million pro Cash at September 30, 2018 forma with de

  4. Slide 4: Mission Statement

    Slide 4: Mission Statement

    MISSION STATEMENT To harness our taurolidine technology for the prevention and treatment of infectious, inflammatory, and other serious diseases First commercial product candidate: Neutrolin® A novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infectio

  5. Slide 5: Corporate Highlights

    Slide 5: Corporate Highlights

    CORPORATE HIGHLIGHTS NEUTROLIN SIGNIFICANT MARKET OPPORTUNITY Non-antibiotic antimicrobial solution designed to prevent costly Estimated 400m vials of catheter lock solutions consumed in the U.S. and dangerous bloodstream infections associated with the use for all indications every year. of central

  6. Slide 6: CorMedix Management Team

    Slide 6: CorMedix Management Team

    CORMEDIX MANAGEMENT TEAM Khoso Baluch CEO Robert Cook CFO Paul Chew, MD Chief Medical Officer Jack Armstrong EVP Technical Operations Elizabeth Masson EVP & Head Of Clinical Operations Antony Pfaffle, MD Chief Scientific Officer John Ortiz VP Regulatory Affairs & Quality Assurance CORMEDIX 6

  7. Slide 7: Current CorMedix Pipeline

    Slide 7: Current CorMedix Pipeline

    CURRENT CORMEDIX PIPELINE DRUG PIPELINE Product Category Indication Preclinical Phase 1 Phase 2 Phase 3 Marketed Hemodialysis Stopped for Efficacy at Interim Review July 2018: FDA Discussions Neutrolin® U.S. Oncology ICU / CCU CMDX-001 Pediatric Neuroblastoma* * Orphan Disease Opportunity MEDICAL DE

  8. Slide 8: Summary and Near-Term Milestones

    Slide 8: Summary and Near-Term Milestones

    SUMMARY AND NEAR-TERM MILESTONES Q2 2018 Q3 2018 Q4 2018 Q1 2019 Phase 3 Trial Stopped at Interim Review for Efficacy Neutrolin® U.S. FDA meeting scheduled: results to be announced 1Q2019 Completed in vivo proof-of-concept data Taurolidine for various medical Platform Medical device applications Dev

  9. Slide 9: Hemodialysis Is Life-Saving

    Slide 9: Hemodialysis Is Life-Saving

    HEMODIALYSIS IS LIFE-SAVING CRBSI is Life-Threatening CORMEDIX 9

  10. Slide 10: Key Benefits of Neutrolin

    Slide 10: Key Benefits of Neutrolin

    KEY BENEFITS OF NEUTROLIN® NEUTROLIN® Non-antibiotic Anti-infective To Prevent CRBSI Prevents and reduces bloodstream infection. Bacteria and fungi, Antibiotic- NEUTROLIN® resistant strains, No reported resistance in Proprietary Formulation a clinical setting Taurolidine – 1.35% (anti-infective, ant

  11. Slide 11: What Are Biofilms and Why Do They Cause Chronic Inflammation and Tissue Damage?

    Slide 11: What Are Biofilms and Why Do They Cause Chronic Inflammation and Tissue Damage?

    What Are Biofilms and Why Do They Cause Chronic Inflammation and Tissue Damage? A B C D A. Planktonic bacteria can be cleared by antibodies, phagocytosis, and are susceptible to antibiotics. B. Adherent bacterial cells form biofilms preferentially on inert surfaces or devitalized tissue, and these s

  12. Slide 12: Biofilms are Highly Tolerant to Antibiotics

    Slide 12: Biofilms are Highly Tolerant to Antibiotics

    Biofilms are Highly Tolerant to Antibiotics Tobramycin vs. planktonic or biofilm Pseudomonas control biofilm dead planktonic Tobramycin rapidly kills planktonic Pseudomonas aeruginosa (●) very effectively, but is not effective against biofilm (●) CORMEDIX Walters et al, Contributions of antibiotic p

  13. Slide 13: Medical Opportunity

    Slide 13: Medical Opportunity

    MEDICAL OPPORTUNITY Despite improvements and initiatives to control infection, biofilm develops very quickly and can lead to life- threatening complications, costing the U.S. healthcare system billions of dollars annually SIGNIFICANT UNMET NEED 250,000 catheter-related bloodstream infections 01 (CRB

  14. Slide 14: Neutrolin: Non-antibiotic Anti-infective To Prevent CRBSI

    Slide 14: Neutrolin: Non-antibiotic Anti-infective To Prevent CRBSI

    NEUTROLIN® Non-antibiotic Anti-infective To Prevent CRBSI NO MICROBIAL RESISTANCE SHOWN BROAD SPECTRUM OF COVERAGE Adaptation of microorganisms to taurolidine has Gram Positive Microorganisms not yet emerged as a factor in the pathogenesis Coagulase-negative Staphylococcus species and of CRBSI Staph

  15. Slide 15: A New Superbug

    Slide 15: A New Superbug

    A NEW SUPERBUG Hard to Detect But Easy to Cause Bloodstream Infections Source: CDC,https://www.cdc.gov/fungal/candida-auris/c-auris-drug-resistant.html CORMEDIX 15

  16. Slide 16: CDC Risk Factor Analysis for C. auris

    Slide 16: CDC Risk Factor Analysis for C. auris

    CDC RISK FACTOR ANALYSIS FOR C. AURIS Bloodstream, wound and ear infections CDC RISK FACTOR Broad-spectrum Recent surgery Diabetes ANALYSIS: antibiotic use Endotracheal tubes, Antifungal Recent Nursing Home feeding tubes, Central No Age Preferences use stay Catheters Infections by C. auris CORMEDIX

  17. Slide 17: Cumulative Cases of C. auris in the US 2017-2018

    Slide 17: Cumulative Cases of C. auris in the US 2017-2018

    CUMULATIVE CASES OF C. AURIS IN THE US 2017-2018 September 2017 November 2018 For 2017 (https://www.cdc.gov/fungal/candida-auris/c-auris-drug-resistant.html) For 2018 (https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html) CORMEDIX 17

  18. Slide 18: CDC Guidelines Upgraded in 2011 to Recommend Use of Antimicrobial Locks

    Slide 18: CDC Guidelines Upgraded in 2011 to Recommend Use of Antimicrobial Locks

    CDC GUIDELINES UPGRADED IN 2011 TO RECOMMEND USE OF ANTIMICROBIAL LOCKS Although antimicrobial locks are associated with a significant reduction in CRBSI, their use was limited CDC Recommendation because of: Use prophylactic antimicrobial lock • Potential for side effects solution in patients with l

  19. Slide 19: Neutrolin Clinically Validated in Real World Study

    Slide 19: Neutrolin Clinically Validated in Real World Study

    NEUTROLIN CLINICALLY VALIDATED IN REAL WORLD STUDY Neutrolin Usage Monitoring Program (NUMP) Neutrolin Significantly Reduces Open-label, post-market observational study Infection and Thrombosis RATE PER 1000 CATHETER DAYS PRIMARY GOAL Benchmark Data Neutrolin Monitor safety and efficacy of CE Marked

  20. Slide 20: FDA Recognizes Potential of Neutrolin

    Slide 20: FDA Recognizes Potential of Neutrolin

    FDA RECOGNIZES POTENTIAL OF NEUTROLIN APPROVAL PATHWAY Designated an investigational new drug by FDA (Catheter LOCK Solution Investigational Trial) 10.5 YEARS Granted FDA Fast Track 5 years exclusivity Potential Market Exclusivity Granted Qualified Infectious Disease Product (QIDP) 5 years exclusivi

  21. Slide 21: LOCK-IT-100 Preventing CRBSI in Dialysis Patients

    Slide 21: LOCK-IT-100 Preventing CRBSI in Dialysis Patients

    LOCK-IT 100 PREVENTING CRBSI IN DIALYSIS PATIENTS DESIGN OBJECTIVE PRIMARY ENDPOINT SECONDARY ENDPOINTS Phase 3, multicenter, double- Demonstrate the efficacy and Time to occurrence of CRBSI Catheter patency: loss of blind, randomized (1:1), active safety of Neutrolin® as a catheter patency followin

  22. Slide 22: LOCK-IT-100 Current Status

    Slide 22: LOCK-IT-100 Current Status

    LOCK-IT 100 CURRENT STATUS Successful Interim Analysis for Convincing Efficacy in July 2018 DSMB Recommended Study Stop: CRMD Remains Blinded Study Closeout Proceeding FDA Meeting Scheduled Results will be announced in 1Q2019 CORMEDIX 22

  23. Slide 23: Thank You

    Slide 23: Thank You

    NYSE American: CRMD @CorMedixInc THANK @Investor & Media Contacts LifeSci Advisors, LLC Dan Ferry daniel@lifesciadvisors.com YOU 617-535-7746 400 Connell Drive Suite 5000 Berkeley Heights, NJ 908.517.9500 CORMEDIX

Source: Internet Archive copy of cormedix.com

More decks from CorMedix Inc.

All 34 CorMedix decks